Nanobiotix (NBTX) announced that partner LianBio (LIAN) has entered into an agreement with Janssen Pharmaceutica, a Johnson & Johnson (JNJ) company, whereby LianBio has assigned to Janssen LianBio’s exclusive rights to develop and commercialize radioenhancer NBTXR3 in China, South Korea, Singapore, and Thailand. This agreement consolidates global development and commercialization rights of NBTXR3 with Janssen; streamlines the global alliance for co-development and registration of the radioenhancer with Nanobiotix; and includes all previously agreed upon economic terms between Nanobiotix and LianBio, including the Nanobiotix entitlement to receive up to an aggregate $220M in potential contingent, development and commercialization milestone payments along with tiered, low double-digit royalties based on net sales of NBTXR3 in Asian territories. Following the deal close, LianBio will support the transition of the asset to Janssen for a period no longer than six months.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NBTX:
- Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets
- Voting Rights and Shares Capital of the Company
- Nanobiotix initiated with an Outperform at Leerink
- Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.
- NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update